Conyers provided Cayman Islands and British Virgin Islands legal advice to Kintor Pharmaceutical Limited (the “Company”) in connection with its HK$1 billion initial public offering of 92,347,500 shares on the Main Board of The Stock Exchange of Hong Kong (Stock code: 9939).

The Company is a clinical-stage novel drug developer in China focused on the proprietary R&D of potential first-in-class and best-in-class drugs for cancers and other androgen receptor-related, or AR-related diseases.

Partner Richard Hall and Counsel Angie Chu of Conyers’ Hong Kong office advised on the matter, working alongside Ashurst Hong Kong and Slaughter and May.

Stay current with our latest legal insights and subscribe today